DNMT1 and non-small cell lung carcinoma: Preclinical data showed that the combination of HDAC and DNMT inhibitors in non-small cell lung cancer (NSCLC) cells correlated with increased interferon-alpha and beta signaling, upregulation of the antigen presentation machinery, and enhanced tumor control associated with increased T-cell infiltrate in the tumor microenvironment and reversion of T-cell exhaustion [33].